title: [Vaccination status in psoriasis patients on immunosuppressant therapy (including biologics)].
abstract: OBJECTIVE
  To evaluate the vaccine coverage of psoriasis patients prior to initiating or changing immunosuppressant therapy, and to verify that the prescribed vaccines have been administered.
  
  
  METHODS
  We conducted a bi-centre, observational, cross-sectional study over 9 months. Psoriasis patients in whom immunosuppressant therapy (comprising cyclosporine, methotrexate, etanercept, infliximab, adalimumab or ustekinumab) was indicated were included. Medical history, previous treatments, vaccination status, viral serology results (for hepatitis B, measles, and chickenpox), and reasons for non-vaccination were assessed via questionnaire.
  
  
  RESULTS
  Sixty-eight patients were included. One third brought their immunization records. Overall, 54.4% had already received immunosuppressant therapy; of these, 9 were up to date for influenza and 3 were up to date for pneumococcus. Only one patient was up to date for all of the recommended vaccinations. A total of 61% of patients were seronegative for hepatitis B. The following vaccines were updated: DTP (in 2 patients), DTP-pertussis (12), influenza (22), pneumococcus (45), and hepatitis B (6). None of the three patients with plans to travel to yellow fever-endemic countries had been vaccinated. In all, 53 (78%) stated that they had already had chickenpox and 43 (63.2%) stated that they had had one of the following three diseases: measles, rubella, or mumps. Fifty-two patients were serologically tested for chickenpox, and 98% were immunized. The most common reasons for not updating the immunization schedule were the absence of any notification or proposal by the patient's doctor and oversight.
  
  
  CONCLUSIONS
  This study should help raise awareness among patients and health professionals concerning the new vaccination recommendations for a population particularly at risk of infection.
authors: Service de dermatologie, hôpitaux de Brabois, CHU de Nancy, 6, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France. Electronic address: axelle_b92@hotmail.com.
authors: A
authors: A
authors: Bonhomme
authors: Service de dermatologie, hôpitaux de Brabois, CHU de Nancy, 6, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
authors: E
authors: E
authors: Fréling
authors: Service de dermatologie, hôpitaux de Brabois, CHU de Nancy, 6, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
authors: M
authors: M
authors: Reigneau
authors: Service de dermatologie, hôpitaux de Brabois, CHU de Nancy, 6, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
authors: C
authors: C
authors: Poreaux
authors: Service de dermatologie, hôpital Legouest, 27, avenue de Plantières, 57070 Metz, France.
authors: A
authors: A
authors: Valois
authors: Service de dermatologie, hôpital Bel Air, centre hospitalier régional de Metz-Thionville, 1-3, rue du Friscaty, 57100 Thionville, France.
authors: F
authors: F
authors: Truchetet
authors: Service de dermatologie, hôpitaux de Brabois, CHU de Nancy, 6, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
authors: A
authors: A
authors: Barbaud
authors: Service de dermatologie, hôpitaux de Brabois, CHU de Nancy, 6, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
authors: J-L
authors: JL
authors: Schmutz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001688:Biological Products / Q000009:adverse effects* / Q000627:therapeutic use*; D019433:Chickenpox Vaccine / Q000008:administration & dosage / Q000276:immunology; D003430:Cross-Sectional Studies; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology; D005260:Female; D005602:France; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D017589:Immunization Programs; D007115:Immunization Schedule; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology; D008297:Male; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology*; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology; D011795:Surveys and Questionnaires; D000073887:Vaccination Coverage; D055815:Young Adult
chemical_list: D001688:Biological Products; D019433:Chickenpox Vaccine; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D017325:Hepatitis B Vaccines; D007166:Immunosuppressive Agents; D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines; D012411:Rubella Vaccine
keywords: Biologics; Biothérapie; Immunosuppressant therapy; Immunosuppresseur; Psoriasis; Vaccination